Cargando…
Target Therapies for Systemic Mastocytosis: An Update
Systemic mastocytosis (SM) results from a clonal proliferation of abnormal mast cells (MCs) in extra-cutaneous organs. It could be divided into indolent SM, smoldering SM, SM with an associated hematologic (non-MC lineage) neoplasm, aggressive SM, and mast cell leukemia. SM is generally associated w...
Autores principales: | Sciumè, Mariarita, De Magistris, Claudio, Galli, Nicole, Ferretti, Eleonora, Milesi, Giulia, De Roberto, Pasquale, Fabris, Sonia, Grifoni, Federica Irene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229771/ https://www.ncbi.nlm.nih.gov/pubmed/35745657 http://dx.doi.org/10.3390/ph15060738 |
Ejemplares similares
-
Case Report: Evolution of KIT D816V-Positive Systemic Mastocytosis to Myeloid Neoplasm With PDGFRA Rearrangement Responsive to Imatinib
por: Sciumè, Mariarita, et al.
Publicado: (2021) -
A case of aggressive systemic mastocytosis with bulky lymphadenopathy showing response to midostaurin
por: Sciumè, Mariarita, et al.
Publicado: (2020) -
Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand?
por: Barbullushi, Kordelia, et al.
Publicado: (2022) -
Treatment of Advanced Systemic Mastocytosis with Midostaurin: Practical Guidance for Optimal Therapy and Management
por: Papayannidis, Cristina, et al.
Publicado: (2022) -
Pediatric Mastocytosis: An Update
por: Giona, Fiorina
Publicado: (2021)